Medical Doctor Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Hugh Nymeyer

Dermatology Seattle, WA Medical Doctor

NPI 1225560550 CMS profile 9564807

515 Minor Ave Ste 210, Seattle, WA 98104

Open in the dashboard

General payments

$6,036

282 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Hugh Nymeyer of Seattle, WA is reported in the CMS Open Payments database as having received $6,036 across 282 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $1,478 67
2023 General $2,194 109
2022 General $1,929 86
2021 General $435 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hugh Nymeyer
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Hugh Nymeyer were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Hugh Nymeyer Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $435 $377 $108–$1,108 $132
2022 $1,929 $514 $143–$1,391 $149
2023 $2,194 $607 $159–$1,674 $160
2024 $1,478 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. AbbVie, Inc. $1,251 71 payments
  2. Janssen Biotech, Inc. $891 47 payments
  3. Sun Pharmaceutical Industries Inc. $824 23 payments
  4. Pfizer Inc. $581 34 payments
  5. Lilly USA, LLC $384 16 payments
  6. Novartis Pharmaceuticals Corporation $354 24 payments
  7. Incyte Corporation $268 10 payments
  8. Amgen Inc. $261 9 payments
  9. UCB, Inc. $232 8 payments
  10. Regeneron Healthcare Solutions, Inc. $207 9 payments
  11. Other $784 31 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $5,632 274 payments
  2. Education $404 8 payments
Products named General payments · program years 2021–2024
  1. TREMFYA $952 48 payments
  2. ILUMYA $739 22 payments
  3. SKYRIZI $617 44 payments
  4. RINVOQ $602 23 payments
  5. CIBINQO $476 33 payments
  6. TALTZ $270 15 payments
  7. Otezla $261 9 payments
  8. DUPIXENT $207 8 payments
  9. SOTYKTU $204 7 payments
  10. OPZELURA $199 9 payments
  11. Other $1,751 86 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

1,319

Median for Dermatology: 534

Drug cost

$472,783

Median for Dermatology: $67,151

Branded share of claims

9.3%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 12 $162,013
Rinvoq Upadacitinib Brand 17 $115,427
Dupixent Pen Dupilumab Brand 25 $98,196
Otezla Apremilast Brand 14 $63,430
Clobetasol Propionate Generic 178 $6,908
Tacrolimus Generic 55 $5,537
Ketoconazole Generic 171 $2,776
Ciclopirox Generic 69 $2,703
Dutasteride Generic 61 $2,471
Doxycycline Hyclate Generic 66 $2,146

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 85 billing codes

Paid by Medicare

$401,316

Of which drugs: $22,587

Medicare patients

1,202

Average age 77

Services billed

6,256

476 women, 726 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 40%
Diabetes 24%
Chronic kidney disease 19%
Ischemic heart disease 18%
Atrial fibrillation 17%
Cancer 15%
Heart failure 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 47 74 $22,342
Injection, bleomycin sulfate, 15 units J9040 Office 11 11 $196
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 28 75 $49

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ILUMYA
  • Sun Pharmaceutical Industries Inc. $209
$209 — —
SKYRIZI
  • AbbVie, Inc. $187
$187 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $84
  • GENZYME CORPORATION $39
$123 25 —
RINVOQ
  • AbbVie, Inc. $116
$116 17 —
HADLIMA
  • Organon LLC $113
$113 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

282 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record